本期内容提示:
1、$西方石油(OXY)$ 、$礼来(LLY)期权异动,后续走势如何看?
2、$Aerie医药(AERI)被收购,哪些眼科药物公司还有配置机会?
3、$Foghorn(FHTX)$ 暴跌,是否有抄底机会?
$欧普康视(SZ300595)$查看全文
郁闷的鞋套-2022-08-23 16:17
$Aerie医药(AERI)$ The purchase price of $15.25 per share represents a premium of 37% to Aerie’s last closing price and represents an equity value of approximately $770 million. The transaction was approved by the board of directors of each company.查看全文
药融云医药大数据2021-12-22 18:11
ROCK抑制剂新药
2021年12月7日,来自日本的参天制药株式会社(总部位于大阪,以下简称“参天”)宣布了其与Aerie Pharmaceuticals(总部位于北卡罗来纳州达勒姆,以下简称“Aerie”)达成了针对Rhopressa® / Rhokiinsa®(Netarsudil ophthalmic solution,奈塔舒地尔滴...查看全文
chuminhua2021-09-16 17:11
9月15日,Aerie Pharmaceuticals宣布TRPM8受体激动剂AR-15512滴眼液治疗干眼症的IIb期COMET-1研究获得积极结果。AR-15512对眼部多种症状和体征有统计学意义改善。Aerie表示接下来将进行另外两项为期3个月的III期疗效研究和一项额外的安全性研究。$Aerie医药(AERI)$查看全文
chuminhua2019-11-19 16:51
11月18日,眼科公司Aerie Pharmaceuticals$Aerie医药(AERI)$ 宣布签署协议,收购西班牙眼科药物公司Avizorex Pharma,后者正在开发用于治疗干眼病的疗法。AVX于今年早些时候完成了一项针对干眼受试者的2a期研究,其主要候选产品AVX-012。AVX-012中的活性成分是TRPM8离子通道的强效选择性激动剂,调...查看全文
越炒股越美2019-03-13 14:56
FDA 三月行动预告:再生元,新基和 Aerie 将迎来新批准
$再生元制药(REGN)$ $新基制药(CELG)$ $Aerie(AERI)$ 本周,FDA将公布三项批准:再生元与赛诺菲特应性皮炎药物将适用于12-17岁青少年;新基Abraxane和罗氏Tecentriq联合治疗乳腺癌;Aerie医药公司将推出青光眼药物Rocklatan。 查看全文ht...查看全文
usbiostock2018-07-24 12:51
$Aerie Pharmaceuticals, Inc. (AERI)$ Roclatan™(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% PDUFA日期:2019年3月14日。查看全文
淘沙见金2017-12-19 04:46
$Aerie Pharmaceuticals, Inc.(AERI)$ FDA居然提前两个多月批了Rhopressa,这帮大爷为了凑2017年批准的数据也是够拼了。照这个趋势,说不定这周也能看到$Spark Therapeutics, Inc.(ONCE)$ 眼药的批准。查看全文
$AERIE PHARMACEUTICALS INC(AERI)$ 8-K - Current report Filed: 2016-06-08 AccNo: 0001193125-16-615909 Size: 12 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 8-K - Current report Filed: 2016-05-11 AccNo: 0001193125-16-586335 Size: 1 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 8-K - Current report Filed: 2016-05-05 AccNo: 0001193125-16-578591 Size: 29 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-05-03 AccNo: 0001628280-16-015353 Size: 3 MB 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 8-K - Current report Filed: 2016-05-02 AccNo: 0001193125-16-572582 Size: 102 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ DEF 14A - Other definitive proxy statements Filed: 2016-04-29 AccNo: 0001628280-16-014984 Size: 668 KB 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 美东时间 2016-05-02 17:00 Q1 2016 Aerie Pharmaceuticals Inc Earnings Call 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 美东时间 2016-05-02 17:00 Q1 2016 Aerie Pharmaceuticals Inc Earnings Call 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 美东时间 2016-05-02 16:30 After Market Close:AERIE PHARMACT Earning Release . Wall St EPS Est ($):-0.66. 网页链接
$AERIE PHARMACEUTICALS INC(AERI)$ 8-K - Current report Filed: 2016-04-12 AccNo: 0001193125-16-537843 Size: 11 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接